FATE THERAPEUTICS INC Debt Conversion, Original Debt, Amount
FATE THERAPEUTICS INC (FATE) reported Debt Conversion, Original Debt, Amount of $22.10 million for the 0-month period ending 2013-10-04, per its 10-Q filed 2014-11-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2015-03-12
- 2013-10-04: Debt Conversion, Original Debt, Amount 0 month $22.10M; Debt Conversion, Original Debt, Amount $22.10M.
| Period end | Debt Conversion, Original Debt, Amount 0 month | Debt Conversion, Original Debt, Amount |
|---|---|---|
| 2013-10-04 | $22.10M 10-Q · filed 2014-11-12 | $22.10M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |